JP2006518756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518756A5 JP2006518756A5 JP2006503797A JP2006503797A JP2006518756A5 JP 2006518756 A5 JP2006518756 A5 JP 2006518756A5 JP 2006503797 A JP2006503797 A JP 2006503797A JP 2006503797 A JP2006503797 A JP 2006503797A JP 2006518756 A5 JP2006518756 A5 JP 2006518756A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- heteroaryl
- aryl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- -1 amino, monosubstituted amino Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44886103P | 2003-02-24 | 2003-02-24 | |
| US10/780,917 US20040209937A1 (en) | 2003-02-24 | 2004-02-19 | Treatment of excessive osteolysis with indolinone compounds |
| PCT/US2004/005283 WO2004075775A2 (en) | 2003-02-24 | 2004-02-23 | Treatment of excessive osteolyisis with indolinone compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518756A JP2006518756A (ja) | 2006-08-17 |
| JP2006518756A5 true JP2006518756A5 (enExample) | 2007-02-15 |
Family
ID=32930497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503797A Withdrawn JP2006518756A (ja) | 2003-02-24 | 2004-02-23 | インドリノン化合物による過度の骨溶解の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040209937A1 (enExample) |
| EP (1) | EP1599207A2 (enExample) |
| JP (1) | JP2006518756A (enExample) |
| KR (1) | KR20050113612A (enExample) |
| AU (1) | AU2004216188A1 (enExample) |
| BR (1) | BRPI0407793A (enExample) |
| CA (1) | CA2516786A1 (enExample) |
| MX (1) | MXPA05008961A (enExample) |
| NZ (1) | NZ541825A (enExample) |
| PL (1) | PL378762A1 (enExample) |
| WO (1) | WO2004075775A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2603445A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| ES2328407T3 (es) * | 2005-09-19 | 2009-11-12 | Pfizer Products Incorporated | Formas salinas solidas de una 2-indolinona sustituida con pirrol. |
| CA2634945A1 (en) * | 2005-12-22 | 2007-10-25 | Novartis Ag | Soluble human m-csf receptor and uses thereof |
| CN101367801B (zh) | 2007-08-15 | 2011-01-12 | 上海恒瑞医药有限公司 | 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用 |
| CA2729253A1 (en) * | 2008-07-02 | 2010-01-07 | Generics [Uk] Limited | Novel process |
| US20110257237A1 (en) * | 2008-07-10 | 2011-10-20 | Generics [Uk] Limited | Process for the preparation of crystalline forms of sunitinib malate |
| CN102239163A (zh) * | 2008-07-24 | 2011-11-09 | 特瓦制药工业有限公司 | 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法 |
| WO2010011834A2 (en) * | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| US10898211B2 (en) | 2015-01-14 | 2021-01-26 | Crossroads Extremity Systems, Llc | Opening and closing wedge osteotomy guide and method |
| US10292713B2 (en) | 2015-01-28 | 2019-05-21 | First Ray, LLC | Freeform tri-planar osteotomy guide and method |
| US10376268B2 (en) | 2015-02-19 | 2019-08-13 | First Ray, LLC | Indexed tri-planar osteotomy guide and method |
| EP3470394B1 (en) * | 2016-06-09 | 2022-01-26 | Yuki Gosei Kogyo Co., Ltd. | Method for preparing 4-(piperidin-4-yl)morpholine |
| US12403012B2 (en) | 2019-07-26 | 2025-09-02 | Crossroads Extremity Systems, Llc | Bone repositioning guide system and procedure |
| AU2021224159A1 (en) | 2020-02-19 | 2022-10-13 | Crossroads Extremity Systems, Llc | Systems and methods for Lapidus repair of bunions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE369359T1 (de) * | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| BR0213185A (pt) * | 2001-10-10 | 2004-09-14 | Sugen Inc | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase |
| WO2003097854A2 (en) * | 2002-05-17 | 2003-11-27 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
-
2004
- 2004-02-19 US US10/780,917 patent/US20040209937A1/en not_active Abandoned
- 2004-02-23 CA CA002516786A patent/CA2516786A1/en not_active Abandoned
- 2004-02-23 BR BRPI0407793-8A patent/BRPI0407793A/pt not_active IP Right Cessation
- 2004-02-23 MX MXPA05008961A patent/MXPA05008961A/es unknown
- 2004-02-23 JP JP2006503797A patent/JP2006518756A/ja not_active Withdrawn
- 2004-02-23 KR KR1020057015602A patent/KR20050113612A/ko not_active Withdrawn
- 2004-02-23 PL PL378762A patent/PL378762A1/pl not_active Application Discontinuation
- 2004-02-23 WO PCT/US2004/005283 patent/WO2004075775A2/en not_active Ceased
- 2004-02-23 AU AU2004216188A patent/AU2004216188A1/en not_active Abandoned
- 2004-02-23 NZ NZ541825A patent/NZ541825A/en unknown
- 2004-02-23 EP EP04713729A patent/EP1599207A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006518756A5 (enExample) | ||
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| AU2006214164B2 (en) | Isoxazole combretastin derivatives for the treatment of disorders | |
| JP2013528602A5 (enExample) | ||
| JP2009534386A5 (enExample) | ||
| JP2017531041A5 (enExample) | ||
| JP2006508981A5 (enExample) | ||
| JP2013516393A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2005500311A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2010531304A5 (enExample) | ||
| JP2005112864A5 (enExample) | ||
| JP2013544276A5 (enExample) | ||
| ATE515505T1 (de) | Heterocyclische fxr-bindende verbindungen | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| JP2011219498A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| MXPA05010712A (es) | Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
| JP2012528166A5 (enExample) | ||
| EP2457918A3 (en) | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | |
| TW200833663A (en) | Therapeutic agents | |
| PE20090151A1 (es) | Derivados de pirimidinona y metodos para su uso | |
| JP2006524222A5 (enExample) | ||
| JP2009519243A5 (enExample) |